Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes

(2014) F. Perosa et al.   JOURNAL OF IMMUNOLOGY

Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis

(2014) P. V. Beum et al.   JOURNAL OF IMMUNOLOGY

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

(2012) M. S. Czuczman et al.   BLOOD

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

(2012) J. Honeychurch et al.   BLOOD

Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma

(2012) Myron S. Czuczman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

(2012) Andres Forero-Torres et al.   CLINICAL CANCER RESEARCH

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2011) M. Dreyling et al.   ANNALS OF ONCOLOGY

Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2011) B. Eichhorst et al.   ANNALS OF ONCOLOGY

Radioimmunotherapy in follicular lymphoma

(2011) Tim Illidge et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

CD20 antibodies: doing the time warp

(2011) M. S. Cragg   BLOOD

CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101

(2011) M. Jak et al.   BLOOD

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

(2011) S. H. Lim et al.   BLOOD

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

(2010) F. Morschhauser et al.   ANNALS OF ONCOLOGY

Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) H. Tilly et al.   ANNALS OF ONCOLOGY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma

(2010) Lan Wu et al.   CANCER LETTERS

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

(2010) S. J. Lemery et al.   CLINICAL CANCER RESEARCH

Rituximab

(2010) Gillian M. Keating   DRUGS

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

(2010) Marinus H.J. van Oers et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

(2010) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma

(2009) B. Li et al.   BLOOD

A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults

(2009) P. Bartolucci et al.   BLOOD

Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope

(2009) Susumu Uchiyama et al.   CANCER SCIENCE

CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells

(2009) M. S. Hayden-Ledbetter et al.   CLINICAL CANCER RESEARCH

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure

(2009) N. A. Johnson et al.   HAEMATOLOGICA

Anti-CD20 monoclonal antibodies: historical and future perspectives

(2009) S. H. Lim et al.   HAEMATOLOGICA

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

(2009) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20

(2009) Jiamu Du et al.   MOLECULAR IMMUNOLOGY

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

(2008) D. M. Goldenberg et al.   BLOOD

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD

CD20 Homo-oligomers Physically Associate with the B Cell Antigen Receptor

(2008) Maria J. Polyak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

(2008) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide

(2008) Jiamu Du et al.   MOLECULAR IMMUNOLOGY

Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma

(2008) Manzurul A. Sikder et al.   Current Hematologic Malignancy Reports